Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate

M. S. Soloway, J. B. DeKernion, R. P. Gibbons, D. E. Johnson, S. A. Loening, J. E. Pontes, G. R. Prout, J. D. Schmidt, W. W. Scott, T. M. Chu, J. F. Gaeta, N. H. Slack, G. P. Murphy

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

There were 121 men with hormonally refractory metastatic cancer of the prostate who were randomized to receive estramustine phosphate or vincristine, or the combination of these 2 agents. All patients had received prior radiation therapy (greater than 2,000 rad). There were 90 patients who could be compared for response. The objective response rates (partial regression or stabilization of disease) for the 3 treatment groups were 26 per cent for estramustine phosphate, 24 per cent for estramustine phosphate plus vincristine and 15 per cent for vincristine. Subjective parameters varied little among the 3 regimens. The median duration of response for those responding to estramustine phosphate was similar (20 weeks) to that for vincristine (22 weeks) and greater than that for the combination (13 weeks). The probability of survival did not Significantly singificantly for patients randomized to each of the 3 regimens. the addition of vincristine to estramustine phosphate did not enhance the response rate achieved by estramustine phosphate alone and vincristine alone produced the lowest response rate. Estramustine phosphate continues to be the most active agent in previously irradiated patients with hormonally refractory metastatic cancer of the prostate.

Original languageEnglish
Pages (from-to)664-667
Number of pages4
JournalJournal of Urology
Volume125
Issue number5
StatePublished - Aug 17 1981
Externally publishedYes

Fingerprint

Estramustine
Vincristine
Prostate
Phosphates
Hormones
Carcinoma
Prostatic Neoplasms
Radiotherapy
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., DeKernion, J. B., Gibbons, R. P., Johnson, D. E., Loening, S. A., Pontes, J. E., ... Murphy, G. P. (1981). Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. Journal of Urology, 125(5), 664-667.

Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. / Soloway, M. S.; DeKernion, J. B.; Gibbons, R. P.; Johnson, D. E.; Loening, S. A.; Pontes, J. E.; Prout, G. R.; Schmidt, J. D.; Scott, W. W.; Chu, T. M.; Gaeta, J. F.; Slack, N. H.; Murphy, G. P.

In: Journal of Urology, Vol. 125, No. 5, 17.08.1981, p. 664-667.

Research output: Contribution to journalArticle

Soloway, MS, DeKernion, JB, Gibbons, RP, Johnson, DE, Loening, SA, Pontes, JE, Prout, GR, Schmidt, JD, Scott, WW, Chu, TM, Gaeta, JF, Slack, NH & Murphy, GP 1981, 'Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate', Journal of Urology, vol. 125, no. 5, pp. 664-667.
Soloway, M. S. ; DeKernion, J. B. ; Gibbons, R. P. ; Johnson, D. E. ; Loening, S. A. ; Pontes, J. E. ; Prout, G. R. ; Schmidt, J. D. ; Scott, W. W. ; Chu, T. M. ; Gaeta, J. F. ; Slack, N. H. ; Murphy, G. P. / Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. In: Journal of Urology. 1981 ; Vol. 125, No. 5. pp. 664-667.
@article{b2f08d2deefb4a959988dd1fc2b309b2,
title = "Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate",
abstract = "There were 121 men with hormonally refractory metastatic cancer of the prostate who were randomized to receive estramustine phosphate or vincristine, or the combination of these 2 agents. All patients had received prior radiation therapy (greater than 2,000 rad). There were 90 patients who could be compared for response. The objective response rates (partial regression or stabilization of disease) for the 3 treatment groups were 26 per cent for estramustine phosphate, 24 per cent for estramustine phosphate plus vincristine and 15 per cent for vincristine. Subjective parameters varied little among the 3 regimens. The median duration of response for those responding to estramustine phosphate was similar (20 weeks) to that for vincristine (22 weeks) and greater than that for the combination (13 weeks). The probability of survival did not Significantly singificantly for patients randomized to each of the 3 regimens. the addition of vincristine to estramustine phosphate did not enhance the response rate achieved by estramustine phosphate alone and vincristine alone produced the lowest response rate. Estramustine phosphate continues to be the most active agent in previously irradiated patients with hormonally refractory metastatic cancer of the prostate.",
author = "Soloway, {M. S.} and DeKernion, {J. B.} and Gibbons, {R. P.} and Johnson, {D. E.} and Loening, {S. A.} and Pontes, {J. E.} and Prout, {G. R.} and Schmidt, {J. D.} and Scott, {W. W.} and Chu, {T. M.} and Gaeta, {J. F.} and Slack, {N. H.} and Murphy, {G. P.}",
year = "1981",
month = "8",
day = "17",
language = "English",
volume = "125",
pages = "664--667",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate

AU - Soloway, M. S.

AU - DeKernion, J. B.

AU - Gibbons, R. P.

AU - Johnson, D. E.

AU - Loening, S. A.

AU - Pontes, J. E.

AU - Prout, G. R.

AU - Schmidt, J. D.

AU - Scott, W. W.

AU - Chu, T. M.

AU - Gaeta, J. F.

AU - Slack, N. H.

AU - Murphy, G. P.

PY - 1981/8/17

Y1 - 1981/8/17

N2 - There were 121 men with hormonally refractory metastatic cancer of the prostate who were randomized to receive estramustine phosphate or vincristine, or the combination of these 2 agents. All patients had received prior radiation therapy (greater than 2,000 rad). There were 90 patients who could be compared for response. The objective response rates (partial regression or stabilization of disease) for the 3 treatment groups were 26 per cent for estramustine phosphate, 24 per cent for estramustine phosphate plus vincristine and 15 per cent for vincristine. Subjective parameters varied little among the 3 regimens. The median duration of response for those responding to estramustine phosphate was similar (20 weeks) to that for vincristine (22 weeks) and greater than that for the combination (13 weeks). The probability of survival did not Significantly singificantly for patients randomized to each of the 3 regimens. the addition of vincristine to estramustine phosphate did not enhance the response rate achieved by estramustine phosphate alone and vincristine alone produced the lowest response rate. Estramustine phosphate continues to be the most active agent in previously irradiated patients with hormonally refractory metastatic cancer of the prostate.

AB - There were 121 men with hormonally refractory metastatic cancer of the prostate who were randomized to receive estramustine phosphate or vincristine, or the combination of these 2 agents. All patients had received prior radiation therapy (greater than 2,000 rad). There were 90 patients who could be compared for response. The objective response rates (partial regression or stabilization of disease) for the 3 treatment groups were 26 per cent for estramustine phosphate, 24 per cent for estramustine phosphate plus vincristine and 15 per cent for vincristine. Subjective parameters varied little among the 3 regimens. The median duration of response for those responding to estramustine phosphate was similar (20 weeks) to that for vincristine (22 weeks) and greater than that for the combination (13 weeks). The probability of survival did not Significantly singificantly for patients randomized to each of the 3 regimens. the addition of vincristine to estramustine phosphate did not enhance the response rate achieved by estramustine phosphate alone and vincristine alone produced the lowest response rate. Estramustine phosphate continues to be the most active agent in previously irradiated patients with hormonally refractory metastatic cancer of the prostate.

UR - http://www.scopus.com/inward/record.url?scp=0019422805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019422805&partnerID=8YFLogxK

M3 - Article

C2 - 7230336

AN - SCOPUS:0019422805

VL - 125

SP - 664

EP - 667

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -